Table I.
Clinical and therapeutical parameters of the ESS and EESS patients.
| Patient no. | Age (years) | Year | Surgical intervention | HP | IHC | Risk factors | Treatment intent and total dose | Survival (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | 55 | 2004 | TH+BSO | ESS G3 | - | Vagina | Adjuvant EBRT TD=50 Gy | |
| 2 | 43 | 2004 | TH+BSO | ESS | - | Vagina | Adjuvant EBRT TD=50 Gy | 168 |
| 3 | 68 | 2006 | TH+BSO | ESS | - | Vagina + parameters | Adjuvant EBRT TD=50 Gy | |
| 4 | 55 | 2009 | TH+BSO | ESS G3 | - | Parameter, miometer | Adjuvant EBRT TD=50 Gy | |
| 5 | 66 | 2016 | TH+BSO | ESS | HG-ESS; ER-, PR- CD10+, VIM+, Ki-67 30% | Adjuvant EBRT TD=50 Gy | 23 | |
| 6 | 64 | 2020 | EESS | Palliative EBRT TD=30 Gy | 11 |
HP, histopathology; IHC, immunohistochemistry; TH+BSO, total hysterectomy + bilateral salpingo-oophorectomy; EBRT, external beam radiotherapy; ESS, endometrial stromal sarcoma; EESS, extrauterine endometrial stromal sarcoma; HG-ESS, high-grade endometrial stromal sarcoma.